Interacting Drugs |
Hyoscyamine, atropine, scopolamine, and phenobarbital vs Brentuximab Vedotin |
Security Level |
|
Mechanism |
Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased. |
Management |
Monitor therapy |
Hyoscyamine, atropine, scopolamine, and phenobarbital vs Brentuximab Vedotin
Post Review about Hyoscyamine, atropine, scopolamine, and phenobarbital vs Brentuximab Vedotin Click here to cancel reply.
Other Interactions of Hyoscyamine, atropine, scopolamine, and phenobarbital
Other Interactions of Brentuximab Vedotin
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.